Cryptos are leaving the margins. They are settling into balance sheets. Bitcoin started the trend, Ethereum followed. Now, some altcoins are attracting the attention of companies. The latest to take this step: Litecoin. Biotech company MEI Pharma has made a strong move. $100 million injected into a treasury strategy exclusively based on this altcoin. A first in the pharmaceutical sector.
This partnership with GSR and MEI Pharma finally brings Litecoin’s mission into an institutional framework.
With GSR, a leader in crypto markets, as a digital asset management advisor, MEI has equipped itself with a formidable duo. Charlie Lee, a recognized pioneer, embodies visionary leadership. GSR, on the other hand, pilots the strategy and manages risks. The result: a hybrid governance between biotech, traditional finance, and crypto.
The announcement quickly stirred up waves. Litecoin jumped more than 12%, temporarily reaching $108. Its transaction volume exploded. The Charlie Lee effect? Certainly. But also the institutional effect.
At the same time, MEIP stock climbed 83% in pre-market, reaching a peak of $9.39. The 29 million shares transaction at $3.42 each was completed, reflecting massive investor enthusiasm.
Luxxfolio Holdings, another listed player, was not left indifferent. Since March, the company has increased its Litecoin treasury by 151.6% per share, now holding a total of 20,084 LTC.
This confirms a trend: Litecoin is no longer confined to individual payments. It is embedding itself into corporate strategies. It becomes a treasury tool. It becomes a trusted asset.
Why did MEI bet on Litecoin and not on Ethereum or Bitcoin? The answer is twofold: efficiency and discretion.
Litecoin was designed to be fast, secure, and decentralized – and it is exciting to see these principles now embraced by a publicly traded company like MEI.
Meanwhile, Litecoin shows massive usage in payments. On BitPay, it sometimes even surpasses Bitcoin in transaction volume.
And beyond the technical narrative, the numbers speak:
The message is clear: Litecoin is no longer a secondary coin. It is an investment tool, a response to volatility, a strategic alternative.
With this unprecedented investment, MEI Pharma is paving the way for a new era for altcoins in corporate finance. But Litecoin is not stopping there. It is now aiming for ETFs, as evidenced by the recently postponed SEC verdict on the Litecoin and Solana ETFs. While Bitcoin settles among tech giants, LTC explores new markets. One step at a time, the gray crypto makes its way to the light.
